Among clinical topics, new data in early settings and continued development of immunotherapies stood out to oncologists as areas that can change their practice in the immediate future.

Among the specific topics commanding healthcare professionals' (HCP) attention were the potential for Sanofi’s Dupixent in eosinophilic esophagitis, Amgen’s tezepelumab in uncontrolled asthma, and Lilly’s Olumiant in atopic dermatitis.

During Q4 earnings calls, biopharmaceutical companies reflected on the cumulative impact of the COVID-19 pandemic. An assessment of US-based physician sentiment (n=62) provides a useful ‘on-the-ground’ perspective to further examine these issues.

Across multiple indications, physicians anticipate 2021 will be an exciting year for advancing treatments across autoimmune and auto-inflammatory conditions.In a study conducted by ZoomRx late December 2020, 107 practicing U.S. rheumatologists

Early stage data showcasing the potential of both genome editing using CRISPR and gene therapy in non-malignant hematological disorders captured attention during this year’s fully virtual ASH annual meeting.A highlight of

Andrew Yukawa is a Consultant in our San Francisco office. His willingness to both learn from his teammates and his generosity in sharing his own skills have made him a key member of

Having weathered many challenges in Q2 2020, biopharmaceutical firms, by and large, presented a case for optimism during Q3 2020 earnings calls. However, alongside this optimistic outlook were a number of voices expressing

Uma Sankar is a Software Development Lead in our Chennai office. She’s been at ZoomRx for over four years and has worked in software development for seven. Uma’s deep understanding of

The prostate-specific antigen (PSA) score has become a critical post-diagnosis tool for oncologists as they discuss prostate cancer disease state with their patients along with their families and caregivers.Oncologist-patient relationships are based

A return to pre-pandemic levels of in-person promotional activity looks increasingly uncertain in H2 2020. Given this uncertainty, pharmaceutical manufacturers, from diversified, multinational firms to more focused, growth-stage companies are navigating the complexities

Oncologists often develop individualized treatment plans to ensure patients are receiving care tailored to their situation. Here are factors influencing their decisions.

Understand how neurology departments across the US and Canada are rapidly adapting their clinical care delivery systems to minimize risk of SARS-CoV-2 transmission.

Evidence shows that the ongoing COVID-19 pandemic disproportionately impacts Black Americans. Here are some recommendations from physicians to advocate for heath equity.

Pharmaceutical manufacturers, from diversified, multinational firms to focused, growth-stage companies are adapting to the reality of COVID-19. Recent Q1 investor calls provide insight into both the impact of the pandemic thus far on

With the ASCO 2020 Annual Meeting just days away, oncologists are nearly universally planning to “attend” this year’s virtual meeting. However, their participation in the meeting will be less in real-time and